Orexo, a pharmaceutical company based in Uppsala, Sweden, has reported its financial results for the first six months of 2017, it was reported yesterday.
The company reported total net revenues of SEK286.4m in the first half of 2017 compared with SEK339.2m in the year-ago period.
The firm posted cash flow from operating activities at SEK76.9m in the first half of 2017, against SEK42.5m in the same period in 2016.
EBITDA was SEK-3.2m compared with SEK-2.3m in the year ago period. Diluted earnings per share were SEK-0.91, compared with SEK- 0.85 for the year ago period.
(EUR1=SEK9.6)
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government